Q1 Earnings Estimate for Soligenix Issued By Zacks Small Cap

Soligenix, Inc. (NASDAQ:SNGX) – Investment analysts at Zacks Small Cap issued their Q1 2025 earnings per share estimates for shares of Soligenix in a report issued on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will post earnings of ($0.67) per share for the quarter. The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.79) EPS and FY2027 earnings at ($1.75) EPS.

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.20 million. During the same period in the prior year, the company earned ($12.66) EPS.

Soligenix Stock Down 1.7 %

Shares of NASDAQ SNGX opened at $2.33 on Thursday. The firm has a 50-day moving average price of $2.35 and a 200 day moving average price of $3.08. Soligenix has a 52 week low of $1.83 and a 52 week high of $14.92. The stock has a market capitalization of $5.85 million, a price-to-earnings ratio of -0.31 and a beta of 2.03.

Institutional Investors Weigh In On Soligenix

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC grew its position in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,094 shares of the biopharmaceutical company’s stock after buying an additional 7,729 shares during the quarter. Geode Capital Management LLC owned 1.04% of Soligenix worth $71,000 at the end of the most recent quarter. 3.60% of the stock is currently owned by institutional investors and hedge funds.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.